53.24
price down icon4.00%   -2.22
after-market アフターアワーズ: 53.20 -0.04 -0.08%
loading
前日終値:
$55.46
開ける:
$55.572
24時間の取引高:
3.82M
Relative Volume:
1.90
時価総額:
$10.29B
収益:
$3.24B
当期純損益:
$348.90M
株価収益率:
29.88
EPS:
1.7817
ネットキャッシュフロー:
$717.02M
1週間 パフォーマンス:
-0.11%
1か月 パフォーマンス:
-4.07%
6か月 パフォーマンス:
+0.83%
1年 パフォーマンス:
-14.21%
1日の値動き範囲:
Value
$52.65
$57.44
1週間の範囲:
Value
$52.45
$57.44
52週間の値動き範囲:
Value
$50.76
$66.28

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
名前
Biomarin Pharmaceutical Inc
Name
セクター
Healthcare (1106)
Name
電話
(415) 506-6700
Name
住所
105 DIGITAL DRIVE, NOVATO, CA
Name
職員
3,221
Name
Twitter
Name
次回の収益日
2026-05-04
Name
最新のSEC提出書
Name
BMRN's Discussions on Twitter

Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
BMRN icon
BMRN
Biomarin Pharmaceutical Inc
53.24 10.72B 3.24B 348.90M 717.02M 1.7817
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
424.36 109.34B 12.32B 4.34B 3.19B 16.86
REGN icon
REGN
Regeneron Pharmaceuticals Inc
702.27 74.35B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
794.70 50.44B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
301.11 39.78B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
297.49 33.02B 5.36B 287.73M 924.18M 2.5229

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-27 再開されました Morgan Stanley Overweight
2026-01-28 再開されました Barclays Overweight
2026-01-20 アップグレード Canaccord Genuity Hold → Buy
2025-12-03 ダウングレード Leerink Partners Outperform → Market Perform
2025-11-06 ダウングレード Stifel Buy → Hold
2025-09-08 開始されました H.C. Wainwright Neutral
2025-09-03 開始されました Raymond James Outperform
2025-07-03 再開されました Morgan Stanley Overweight
2025-02-24 アップグレード Oppenheimer Perform → Outperform
2024-11-15 開始されました Wolfe Research Outperform
2024-10-30 ダウングレード William Blair Outperform → Mkt Perform
2024-10-10 再開されました Raymond James Outperform
2024-08-20 アップグレード Bernstein Mkt Perform → Outperform
2024-05-17 ダウングレード Robert W. Baird Outperform → Neutral
2024-05-14 開始されました Evercore ISI Outperform
2023-11-15 開始されました Wells Fargo Overweight
2023-10-23 アップグレード Bernstein Underperform → Mkt Perform
2023-09-28 開始されました Raymond James Mkt Perform
2023-09-18 開始されました UBS Buy
2023-07-27 開始されました Scotiabank Sector Perform
2023-07-05 アップグレード BMO Capital Markets Market Perform → Outperform
2023-06-14 再開されました Credit Suisse Outperform
2023-03-21 開始されました Bernstein Underperform
2023-02-22 ダウングレード Oppenheimer Outperform → Perform
2023-02-21 開始されました Citigroup Neutral
2023-01-30 開始されました BMO Capital Markets Market Perform
2023-01-18 開始されました Canaccord Genuity Hold
2022-10-31 アップグレード Oppenheimer Perform → Outperform
2022-07-13 開始されました Cantor Fitzgerald Overweight
2022-06-13 再開されました Wedbush Neutral
2022-04-25 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-11-22 アップグレード William Blair Mkt Perform → Outperform
2021-10-07 再開されました Jefferies Buy
2021-09-09 アップグレード Stifel Hold → Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-03-04 再開されました Guggenheim Buy
2021-03-01 アップグレード Evercore ISI In-line → Outperform
2020-08-20 ダウングレード Citigroup Buy → Neutral
2020-08-20 ダウングレード William Blair Outperform → Mkt Perform
2020-08-19 ダウングレード Evercore ISI Outperform → In-line
2020-08-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-08-19 ダウングレード Stifel Buy → Hold
2020-07-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-07-06 繰り返されました Citigroup Buy
2020-01-28 開始されました BMO Capital Markets Market Perform
2020-01-27 開始されました BMO Capital Markets Market Perform
2020-01-24 アップグレード RBC Capital Mkts Sector Perform → Outperform
2019-11-27 アップグレード Barclays Equal Weight → Overweight
2019-11-12 開始されました SunTrust Buy
2019-10-17 再開されました BofA/Merrill Buy
2019-05-23 再開されました Citigroup Buy
2019-04-09 再開されました Raymond James Outperform
2019-01-02 ダウングレード Raymond James Outperform → Mkt Perform
2018-12-14 開始されました Wolfe Research Outperform
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-08-07 繰り返されました Stifel Buy
2018-08-03 繰り返されました Stifel Buy
すべてを表示

Biomarin Pharmaceutical Inc (BMRN) 最新ニュース

pulisher
May 05, 2026

BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised - sharewise.com

May 05, 2026
pulisher
May 05, 2026

BioMarin (NASDAQ: BMRN) Q1 profit drops as $4.8B Amicus acquisition ramps - Stock Titan

May 05, 2026
pulisher
May 05, 2026

BioMarin Pharmaceutical Q1 Revenue Beat Backed by Voxzogo Strength, Diversified Portfolio, Wedbush Says - marketscreener.com

May 05, 2026
pulisher
May 05, 2026

BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says - marketscreener.com

May 05, 2026
pulisher
May 05, 2026

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2026 Earnings Call Transcript - Insider Monkey

May 05, 2026
pulisher
May 05, 2026

BioMarin Pharmaceutical Q1 2026: $0.76 EPS Falls Short — Deep Dive - AlphaStreet

May 05, 2026
pulisher
May 05, 2026

Bernstein SocGen lowers BioMarin stock price target on guidance update By Investing.com - Investing.com Canada

May 05, 2026
pulisher
May 05, 2026

MSN Money - MSN

May 05, 2026
pulisher
May 05, 2026

Evercore ISI raises BioMarin stock price target on valuation gap - Investing.com

May 05, 2026
pulisher
May 05, 2026

BMRN Q1 Deep Dive: Amicus Acquisition, Pipeline Milestones, and Order Dynamics Shape Outlook - TradingView

May 05, 2026
pulisher
May 04, 2026

BioMarin Boosts 2026 Outlook After Amicus Deal - TipRanks

May 04, 2026
pulisher
May 04, 2026

BioMarin Q1 2026 Earnings Preview: Revenue Growth Expected to SlowNews and Statistics - IndexBox

May 04, 2026
pulisher
May 04, 2026

BioMarin Pharmaceutical Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

May 04, 2026
pulisher
May 04, 2026

Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics - Yahoo Finance

May 04, 2026
pulisher
May 04, 2026

BioMarin (BMRN) Q1 2026 Earnings Transcript - AOL.com

May 04, 2026
pulisher
May 04, 2026

BMRN: Amicus acquisition drives 20% 2026 revenue growth outlook and portfolio expansion - TradingView

May 04, 2026
pulisher
May 04, 2026

BioMarin Q1 2026 slides: revenue beats forecast, eyes 20% growth - Investing.com

May 04, 2026
pulisher
May 04, 2026

BioMarin Pharmaceutical Q1 Earnings Call Highlights - Yahoo Finance

May 04, 2026
pulisher
May 04, 2026

Earnings call transcript: BioMarin Q1 2026 beats EPS forecasts, stock dips slightly - Investing.com

May 04, 2026
pulisher
May 04, 2026

Transcript: Biomarin Pharmaceutical Q1 2026 Earnings Conference Call - Benzinga

May 04, 2026
pulisher
May 04, 2026

BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates - Yahoo Finance

May 04, 2026
pulisher
May 04, 2026

BioMarin Pharmaceutical Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:BMRN) 2026-05-04 - Seeking Alpha

May 04, 2026
pulisher
May 04, 2026

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Q1 Earnings Miss Masked by Raised 2026 Guidance - ChartMill

May 04, 2026
pulisher
May 04, 2026

BioMarin Pharmaceutical Q1 Non-GAAP Earnings Fall, Revenue Rises; 2026 Guidance Revised - marketscreener.com

May 04, 2026
pulisher
May 04, 2026

Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Reports Q1 Revenue $766.2M, vs. FactSet Est of $752.2M - marketscreener.com

May 04, 2026
pulisher
May 04, 2026

BioMarin beats estimates, raises guidance on Amicus deal By Investing.com - Investing.com Nigeria

May 04, 2026
pulisher
May 04, 2026

(BMRN) BioMarin Pharmaceutical Expects Full Year 2026 Revenue Range $3.83B$3.93B - marketscreener.com

May 04, 2026
pulisher
May 04, 2026

BioMarin beats estimates, raises guidance on Amicus deal - Investing.com

May 04, 2026
pulisher
May 04, 2026

BioMarin: Q1 Earnings Snapshot - marketscreener.com

May 04, 2026
pulisher
May 04, 2026

Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q1 Adjusted EPS $0.76 per Share, vs. FactSet Est of $0.91 - marketscreener.com

May 04, 2026
pulisher
May 04, 2026

BioMarin Pharmaceutical (NASDAQ:BMRN) Misses Q1 CY2026 Revenue Estimates - Yahoo Finance

May 04, 2026
pulisher
May 04, 2026

BioMarin (NASDAQ: BMRN) raises 2026 sales view following Amicus deal - Stock Titan

May 04, 2026
pulisher
May 04, 2026

BioMarin Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 04, 2026
pulisher
May 04, 2026

BioMarin Reports First Quarter 2026 Financial and Operating Results - PR Newswire

May 04, 2026
pulisher
May 04, 2026

Mucopolysaccharidoses Market to Reach USD 4,389.85 Million - openPR.com

May 04, 2026
pulisher
May 03, 2026

BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To Expect - Yahoo Finance

May 03, 2026
pulisher
May 02, 2026

BioMarin Pharmaceutical Q1 2026 earnings preview - MSN

May 02, 2026
pulisher
May 02, 2026

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting - The AI Journal

May 02, 2026
pulisher
May 02, 2026

Biomarin presents new data on the effect of long-term treatment with Voxzogo® (vosoritide) on arm span, bone health and growth in children with achondroplasia - marketscreener.com

May 02, 2026
pulisher
May 02, 2026

Six-year study finds bone health maintained in children on VOXZOGO - Stock Titan

May 02, 2026
pulisher
May 02, 2026

Assessing BioMarin (BMRN) Valuation As Shares Show Recent Weakness And DCF Signals Deep Discount - Sahm

May 02, 2026
pulisher
May 01, 2026

BioMarin acquires Amicus Therapeutics for $4.8bn - MSN

May 01, 2026
pulisher
May 01, 2026

BioMarin Pharmaceutical Inc expected to post earnings of 79 cents a shareEarnings Preview - TradingView

May 01, 2026
pulisher
May 01, 2026

BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset - Sahm

May 01, 2026
pulisher
May 01, 2026

How Will BioMarin Pharmaceutical Stock React To Its Upcoming Earnings? - Trefis

May 01, 2026
pulisher
May 01, 2026

BIOMARIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc.BM - TMX Newsfile

May 01, 2026
pulisher
May 01, 2026

Short Interest in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Rises By 14.9% - MarketBeat

May 01, 2026
pulisher
May 01, 2026

BMRN News | BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) - ChartMill

May 01, 2026
pulisher
Apr 30, 2026

Precision Trading with Biomarin Pharmaceutical Inc. (BMRN) Risk Zones - Stock Traders Daily

Apr 30, 2026
pulisher
Apr 30, 2026

BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust - Sahm

Apr 30, 2026
pulisher
Apr 30, 2026

BioMarin Pharmaceutical Earnings Notes - Trefis

Apr 30, 2026

Biomarin Pharmaceutical Inc (BMRN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$28.32
price down icon 0.14%
$50.44
price up icon 0.48%
$95.50
price down icon 3.88%
$139.44
price down icon 0.41%
$147.21
price down icon 0.47%
ONC ONC
$297.49
price up icon 0.12%
大文字化:     |  ボリューム (24 時間):